ArticleOpen medicine (Warsaw, Poland)2025
Polyphyllin II inhibits thyroid cancer cell growth by simultaneously inhibiting glycolysis and oxidative phosphorylation.
Article in Open medicine (Warsaw, Poland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thyroid cancer is the most common malignancy of the endocrine system, and effective treatments for metastatic disease are still lacking. Targeting both glycolysis and oxidative phosphorylation (OXPHOS) simultaneously represents a novel approach to cancer therapy. While polyphyllin has been shown to modulate cellular metabolism in various cancers, its role in thyroid cancer remains unexplored. Purpose: This study aimed to explore the antitumor effects and underlying mechanisms of polyphyllin in thyroid cancer. Methods: Thyroid cancer cells were treated with varying concentrations of Polyphyllin I, II, VI, and VII. Cell viability was assessed using the CCK-8 assay to identify the most effective polyphyllin compound and its optimal dosage. Colony formation and EdU incorporation assay were performed to evaluate cell proliferation, while Transwell assays were used to assess cell invasion. Cell migration ability was examined using the wound healing assay. The effect of Polyphyllin II on OXPHOS was evaluated using an extracellular oxygen consumption rate (OCR) assay kit. Glucose uptake, lactate production, glycolysis-related protein expression, and the extracellular acidification rate (ECAR) were measured to assess the effects of Polyphyllin II on glycolysis in thyroid cancer cells. Flow cytometry and western blotting were conducted to detect apoptosis. Results: Polyphyllin I, II, VI, and VII all inhibit the proliferation of thyroid cancer cells, with Polyphyllin II showing the most potent inhibitory effect. Polyphyllin II suppresses cell proliferation, invasion, and migration of thyroid cancer cells, while also promoting apoptosis. Mechanism studies reveal that Polyphyllin II inhibits extracellular OCR, basal respiration, maximum respiration, ATP-linked respiration, spare respiration capacity, glucose uptake, lactate production, glycolytic rate-limiting enzymes, and the ECAR in thyroid cancer cells. Conclusion: Polyphyllin II simultaneously inhibits glycolysis and OXPHOS, thereby suppressing the invasion, migration, and proliferation of thyroid cancer cells, while also promoting apoptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.